Acrivon Therapeutics (ACRV) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 0.5% versus a loss of 30.3%. Telomir Pharmaceuticals is the larger company by market cap ($84.7 million vs $80.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | TELO |
|---|---|---|
| Share price | $1.87 | $1.15 |
| Market cap | $80.14M | $84.66M |
| 1-day change | -0.53% | +2.68% |
| YTD return | -22.41% | -13.53% |
| 1-year return | -0.53% | -30.30% |
| EPS (TTM) | $-1.88 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $1.82 |
| 52-week low | $1.27 | $0.888 |
| Distance from 52-week high | -47.47% | -36.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +514.97% | +247.83% |
| Average volume | 361.40K | 97.98K |
| Shares outstanding | 42.85M | 73.62M |
| Employees | 74 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRV has outperformed TELO by 29.8 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Healthcare · Biotechnology · 74 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Healthcare · Biotechnology
ACRV vs TELO FAQ
Which is bigger, Acrivon Therapeutics or Telomir Pharmaceuticals?
Telomir Pharmaceuticals (TELO) is larger, with a market capitalization of $84.66M compared with $80.14M for Acrivon Therapeutics (ACRV).
Which stock has performed better over the past year, ACRV or TELO?
ACRV returned -0.53% over the past 12 months, compared with -30.30% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.